Agilent TechnologiesFRA:AG8 -0.74%94 Current Ratio is 2.10 as of Apr. 2026, which is 5% below its 10-year median of 2.21. GuruFocus rates FRA:AG8 with a GF Score™ of 94/100 and a GF Value™ of €126.57 (Modestly Undervalued). The stock has 1 warning sign investors should review. Among 214 Medical Diagnostics & Research companies, Agilent Technologies ranks better than 50.93% on this metric.
The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. Agilent Technologies's current ratio for the quarter that ended in Apr. 2026 was 2.10.
Agilent Technologies has a current ratio of 2.10. It generally indicates good short-term financial strength.
The historical rank and industry rank for Agilent Technologies's Current Ratio or its related term are showing as below:
FRA:AG8'
s Current Ratio Range Over the Past 10 Years
Min: 1.53 Med: 2.21 Max: 3.85
Current: 2.1
During the past 13 years, Agilent Technologies's highest Current Ratio was 3.85. The lowest was 1.53. And the median was 2.21.
FRA:AG8's Current Ratio is ranked better than 50.93% of 214
companies
in the Medical Diagnostics & Research industry
Industry Median: 2.06
vs FRA:AG8: 2.10
Agilent Technologies (FRA:AG8) Current Ratio Explanation
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
Agilent Technologies Current Ratio Related Terms
Agilent Technologies Current Ratio Historical Data
* Premium members only.
The historical data trend for Agilent Technologies's Current Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:AG8 vs NTRA, WAT, IDXX: Current Ratio Comparison
For the Diagnostics & Research subindustry, Agilent Technologies's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Agilent Technologies Current Ratio vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Agilent Technologies's Current Ratio distribution charts can be found below:
* The bar in red indicates where Agilent Technologies's Current Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Agilent Technologies (FRA:AG8) has a Current Ratio of 2.10 as of Apr. 2026. This is near median its historical median of 2.21. Over the past decade, Agilent Technologies' Current Ratio has ranged from 1.53 to 3.85. According to the industry distribution chart, Agilent Technologies ranks #105 out of 214 companies in the Medical Diagnostics & Research industry, placing it in the top 49.1%.
Is Agilent Technologies' Current Ratio too high?
Agilent Technologies' current Current Ratio of 2.10 is near median its 10-year median of 2.21. Over the past 10 years, this metric has ranged from a low of 1.53 to a high of 3.85. The Medical Diagnostics & Research industry median Current Ratio is 2.06. Agilent Technologies' value of 2.10 is 1.9% above this industry median. Based on the distribution chart, Agilent Technologies ranks #105 out of 214 companies in the Medical Diagnostics & Research industry, which is above the industry midpoint. Overall, Agilent Technologies has a GF Score™ of 94/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Agilent Technologies' Current Ratio compare to NTRA and WAT?
According to the Medical Diagnostics & Research industry distribution chart, Agilent Technologies ranks #105 out of 214 companies for Current Ratio. This puts Agilent Technologies in the upper half of its industry. The industry median Current Ratio is 2.06. Agilent Technologies' value of 2.10 is 1.9% above this benchmark. Historically, Agilent Technologies' own Current Ratio has ranged from 1.53 to 3.85 over the past decade. While the company's 10-year median is 2.21 vs. the industry median of 2.06, Agilent Technologies has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for a Medical Diagnostics & Research company?
The median Current Ratio among Medical Diagnostics & Research companies is 2.06, based on 214 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Agilent Technologies's current Current Ratio of 2.10 is 1.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Medical Diagnostics & Research industry, the median Current Ratio is 2.06 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Agilent Technologies's current Current Ratio is 2.10, which is near median its own 10-year median of 2.21. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Agilent Technologies stock overvalued right now?
Based on GuruFocus' analysis, Agilent Technologies (FRA:AG8) is currently considered Modestly Undervalued. The stock's GF Value™ is €126.57, compared to a current price of €113.65 — trading 10.2% below its estimated fair value. The current Current Ratio is 2.10, which is near median its 10-year median of 2.21 and 1.9% above the Medical Diagnostics & Research industry median of 2.06. Agilent Technologies' overall GF Score™ is 94/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For Agilent Technologies (FRA:AG8), the current Current Ratio is 2.10 as of Apr. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Agilent Technologies (FRA:AG8) Overvalued in 2026?
Based on GuruFocus' analysis, Agilent Technologies stock appears to be undervalued.
The current stock price of €113.65 is trading 10.2% below its estimated GF Value™ of €126.57.
GuruFocus considers Agilent Technologies to be Modestly Undervalued.
Key valuation signals for FRA:AG8:
Current Ratio: 2.10 (near median its 10-year median of 2.21)
GF Value™: €126.57 vs. price of €113.65 (10.2% below fair value)
Industry Position: 1.9% above the Medical Diagnostics & Research median (#105 of 214)
No single metric tells the full story. See the FRA:AG8 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Originally spun out of Hewlett-Packard in 1999, Agilent has evolved into a leading life science and diagnostic firm. Today, Agilent's measurement technologies serve a broad base of customers with its three operating segments: life science and diagnostics, cross lab operations consisting of consumables and services, and applied end markets. Over half of its sales are generated from the biopharmaceutical, chemical, and advanced materials end markets, which we view as the stickiest end markets, but it also supports clinical lab, environmental, forensics, food, academic, and government-related organizations. The company is geographically diverse, with operations in the US and China representing the largest country concentrations.
94GF Score
Get the complete analysis for FRA:AG8
Current Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:AG8 has been successfully added to your 
